Key facts
- It has raised $39.1M; the latest was Later Stage VC in Oct 2025.
- Notable investors include Innovate UK, Wellcome Trust, Cambridge Innovation Capital, Accelerate@Babraham, Cancer Research Horizons — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Mosaic Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Mosaic Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Mosaic Therapeutics
Operator of an oncology therapeutics company intended to tackle cancers with substantial unmet needs. The company utilizes artificial intelligence to prioritize key anti-cancer targets and to genetically identify those patient groups most likely to respond to treatments developed against those targets by using next-generation tumor systems and advanced genomic technologies, enabling patients to treat cancers based on their tissue of origin.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2020
- Employees
- 26
- Website
- mosaic-tx.com/
- Ownership
- Privately Held (backing)
Mosaic Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Mosaic Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Mosaic Therapeutics in its N-PORT filings yet. We sweep new filings monthly.